No 03 2021

Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell therapies that can treat underlying disease.

Innovent Biologics has announced a strategic collaboration with Eli Lilly and Company ("Lilly") to advance novel medicines in oncology and immunology.

A 2026 population‑based cohort study covering Denmark, Finland, Iceland, Norway and Sweden analysed 1‑year relative survival and excess mortality in cancer patients diagnosed during March–December 2020 versus expectations from 2011–2019.

Medivir has completed a directed share issue of SEK 45 million (before issue costs) to Carl Bennet AB, issuing 90 million new shares at SEK 0.50 per share—a 19 percent premium to the closing price on February 5, 2026.

Denmark’s recent regulatory moves are increasingly described as a competitive advantage for the country’s life science sector, as the government aligns national rules with the EU Pharmaceutical Package and the forthcoming Biotech Act, according to analysis from Pharmadanmark and EU policy commentators.

When Cancer Crosslinks took place in Oslo on January 22, it marked the meeting’s 18th anniversary. It’s “really coming of age,” jokes Jutta Heix, the Head of International Affairs at Oslo Cancer Cluster, which organizes the meeting.

Cereno Scientific is broadening the development focus of its HDAC inhibitor CS014 to pulmonary hypertension associated with interstitial lung disease (PH-ILD).